Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
On 29-May-2025, the patient took first capsule, on 31-may-2025, the patient took second and then forgot the remaining two capsules; Case reference number US-BN-2025-001021 is a spontaneous case report initially received from a pharmacist via Communication (reference number: USBAV25-1336) on 06-Jun-2025 and concerns a patient of unspecified age and gender. The patient's relevant medical history and concomitant medications were not provided. On 29-May-2025, the patient took first dose of Vivotif vaccine (batch number: unknown) at unknown dose, or route for unknown indication. On 31-May-2025, two days after first dose, the patient took second dose of Vivotif vaccine (batch number: unknown) at unknown dose or route of administration. The patient forgot the remaining two capsules (explicitly coded as 'missed dose'). As reported, the physician was wondering if the patient takes third dose today and their fourth dose on the 8th or if need to completely restart the series. At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. No further information provided.; Reporter's Comments: A patient of unspecified age and gender took second dose of Vivotif vaccine, two days after first dose at unknown dose or route of administration. The patient forgot the remaining two capsules which is considered as missed dose. Product dose omission issue is considered listed per company convention. The patient's relevant medical history and concomitant medications were not provided. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unspecified age and gender took second dose of Vivotif vaccine, two days after first dose at unknown dose or route of administration. The patient forgot the remaining two capsules which is considered as missed dose. Product dose omission issue is considered listed per company convention. The patient's relevant medical history and concomitant medications were not provided. At this point, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.